Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
First Claim
1. A method for treating fibromyalgia comprising administering to a patient afflicted with such condition a therapeutically effective amount for treating such condition of a non-ergot dopamine D2/D3 receptor agonist or a pharmacologically acceptable acid addition salt thereof, alone or in association with a pharmaceutically acceptable carrier, wherein the dopamine D2/D3 receptor agonist is a tetrahydro-benzthiazole compound of formula I:
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention is directed to metho s for the treatment of human patients afflicted with fibromyalgia using a non-ergot dopamine receptor D2/D3 agonist. In particular, patients are treated with a therapeutically effective amount of tetrahydro-benzthiazole or 3(H)-indolone compounds that are dopamine agonists. More specifically, the compounds 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzo-thiazole or 4-[2-(dipropylamino)-ethyl]-1,3-dihydro-2H-indol-2-one are administered to fibromyalgia patients to reduce the musculoskeletal pain symptoms associated with fibromyalgia.
-
Citations
5 Claims
- 1. A method for treating fibromyalgia comprising administering to a patient afflicted with such condition a therapeutically effective amount for treating such condition of a non-ergot dopamine D2/D3 receptor agonist or a pharmacologically acceptable acid addition salt thereof, alone or in association with a pharmaceutically acceptable carrier, wherein the dopamine D2/D3 receptor agonist is a tetrahydro-benzthiazole compound of formula I:
Specification